SpringWorks Therapeutics Inc (SWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has a cash flow conversion efficiency ratio of -0.165x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.76 Million) by net assets ($417.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SWTX net asset quality index to measure how much of total assets are equity-financed.
SpringWorks Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SWTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
SpringWorks Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CCOOP Group Co Ltd
SHE:000564
|
-0.008x |
|
Financière Amuse TopCo SAS
ST:ASMDEE-B
|
0.068x |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
0.042x |
|
Fluidra
MC:FDR
|
0.086x |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
0.006x |
|
Grupa KĘTY SA
WAR:KTY
|
0.134x |
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
0.016x |
|
IGO Ltd
AU:IGO
|
0.014x |
Annual Cash Flow Conversion Efficiency for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of SpringWorks Therapeutics Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see SWTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $481.10 Million | $-175.60 Million | -0.365x | -2.59% |
| 2023-12-31 | $626.22 Million | $-222.79 Million | -0.356x | -22.92% |
| 2022-12-31 | $558.19 Million | $-161.56 Million | -0.289x | +4.39% |
| 2021-12-31 | $422.40 Million | $-127.88 Million | -0.303x | -423.89% |
| 2020-12-31 | $557.06 Million | $-32.19 Million | -0.058x | +60.77% |
| 2019-12-31 | $322.07 Million | $-47.44 Million | -0.147x | -119.40% |
| 2018-12-31 | $-19.37 Million | $-14.71 Million | 0.759x | -10.99% |
| 2017-12-31 | $-2.62 Million | $-2.24 Million | 0.853x | +460.05% |
| 2010-12-31 | $36.81 Million | $5.61 Million | 0.152x | -20.90% |
| 2009-12-31 | $27.15 Million | $5.23 Million | 0.193x | -41.95% |
| 2008-12-31 | $21.41 Million | $7.10 Million | 0.332x | -2.79% |
| 2007-12-31 | $16.69 Million | $5.70 Million | 0.341x | +440.29% |
| 2006-12-31 | $11.85 Million | $748.00K | 0.063x | -74.88% |
| 2005-12-31 | $15.94 Million | $4.01 Million | 0.251x | -4.37% |
| 2004-12-31 | $14.57 Million | $3.83 Million | 0.263x | -49.59% |
| 2001-12-31 | $26.45 Million | $13.79 Million | 0.521x | +561.99% |
| 2000-12-31 | $20.14 Million | $1.59 Million | 0.079x | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more